This trial represents the first major advancement in second-line GIST treatment in over two decades, potentially transforming the therapeutic landscape. Cogent Biosciences announced positive results ...
Subcutaneous dulaglutide, semaglutide, and tirzepatide demonstrated a similar GI safety among patients with type 2 diabetes.
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback